GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Cirrhosis Liver/ACLF—Contrasting Perspectives From the East and West

ACLF—Contrasting Perspectives From the East and West

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated November 1, 2025

Quick Answer

Acute-on-chronic liver failure (ACLF) is a severe condition characterized by acute decompensation in patients with chronic liver disease, accompanied by organ failures and high short-term mortality. However, the definitions, triggers, and management strategies for ACLF differ significantly between Eastern (Asia–Pacific) and Western perspectives.


Acute-on-chronic liver failure (ACLF) is a severe condition characterized by acute decompensation in patients with chronic liver disease, accompanied by organ failures and high short-term mortality. However, the definitions, triggers, and management strategies for ACLF differ significantly between Eastern (Asia–Pacific) and Western perspectives. Below is a detailed comparison of the contrasting approaches from the East and West:

---

### **1. Definitions: APASL vs AASLD/CLIF**

#### **Eastern Perspective: APASL (Asia–Pacific Association for the Study of the Liver)**

  • **Definition**: ACLF is primarily defined as an *acute hepatic insult* in a patient with chronic liver disease or compensated cirrhosis. This insult leads to:
  • **Jaundice** (bilirubin ≥5 mg/dL)
  • **Coagulopathy** (INR ≥1.5)
  • Complications within 4 weeks, including **ascites** and/or **encephalopathy**.
  • **Focus**: Liver failure is considered the primary event, with extrahepatic organ dysfunction being secondary.
  • **Triggers**: Common acute hepatic insults include:
  • Flare of hepatitis B virus (HBV)
  • Acute alcoholic hepatitis
  • Drug-induced liver injury
  • Infection
  • **Approach**: The definition emphasizes liver-centric failure and its progression to multi-organ dysfunction.

#### **Western Perspective: AASLD/CLIF (American Association for the Study of Liver Diseases / Chronic Liver Failure Consortium)**

  • **Definition**: ACLF is defined in patients with *decompensated cirrhosis* based on the presence of **organ failures**, assessed using:
  • **CLIF-SOFA/CLIF-OF score**, which evaluates:
  • Liver function
  • Kidney function
  • Brain function
  • Coagulation
  • Circulation
  • Respiration
  • Associated 28-day mortality risk is a key component of the definition.
  • **Focus**: ACLF is considered a **multiorgan failure syndrome** in cirrhosis, where organ dysfunctions occur simultaneously.
  • **Triggers**: Common triggers include:
  • Infection (e.g., spontaneous bacterial peritonitis)
  • Active alcohol use
  • Gastrointestinal bleeding
  • **Approach**: The definition highlights systemic involvement and multiorgan failure.

---

### **2. Management: East vs West**

#### **Western Perspective: AASLD/EASL-CLIF**

  • **Early ICU-Level Care**: Patients with ACLF are often admitted to intensive care units for close monitoring and aggressive interventions.
  • **Sepsis Control**: Infection is a frequent trigger, and early, aggressive management of sepsis is emphasized.
  • **Renal Replacement Therapy (RRT)**: For acute kidney injury or hepatorenal syndrome.
  • **Vasopressors**: Used to manage circulatory dysfunction and maintain hemodynamic stability.
  • **Transplantation**: There is a strong emphasis on early liver transplant evaluation. The approach follows a "transplant or die" paradigm for high-grade ACLF, as transplantation is often the definitive treatment for survival.
  • **Focus**: Systemic support and transplant-centered care.

#### **Eastern Perspective: APASL**

  • **Medical Management and Liver Regeneration**:
  • **Antiviral Therapy**: For HBV flares, antiviral agents are used to control the underlying hepatic insult.
  • **Albumin Infusions**: To improve circulatory dysfunction and reduce inflammation.
  • **Plasma Exchange**: Used in some centers to support liver function and remove toxins.
  • **Stem-Cell/Regenerative Therapies**: Experimental approaches are employed in select centers to promote liver regeneration.
  • **Transplantation**: While liver transplantation is important, access to transplantation is often limited in resource-constrained settings. As a result, there is greater focus on bridging and rescue therapies.
  • **Focus**: Liver-centric management and regeneration-friendly approaches.

---

### **3. Why This Contrast Matters**

Understanding the differences between Eastern and Western approaches to ACLF is crucial for a comprehensive perspective on the disease. Here’s why:

#### **Recognition of ACLF Across Different Etiologies**

  • In Asia, HBV-related ACLF is more prevalent, whereas alcohol-related ACLF and metabolic dysfunction-associated liver disease (MASLD, formerly NAFLD) are more common in the West.
  • Recognizing the specific triggers and etiologies helps tailor early diagnosis and interventions.

#### **Adaptation to Resource-Limited Settings**

  • In regions where liver transplantation is not readily available, Eastern approaches focus on medical management and regenerative therapies as alternatives to transplantation.
  • Western approaches, on the other hand, emphasize transplantation as the definitive treatment for ACLF.

#### **Convergence Toward Unified Management**

  • Both Eastern and Western perspectives are gradually converging toward a phenotype-based, transplant-aware approach to ACLF.
  • There is growing interest in combining liver regeneration strategies with systemic support for multiorgan failure.

---

### **Conclusion**

The contrasting perspectives from the East and West highlight the complexity of ACLF as a global health challenge. While the East focuses on liver-centric mechanisms and regeneration, the West emphasizes systemic multiorgan failure and transplantation. Understanding these differences enables clinicians to:

  • Recognize ACLF early, regardless of etiology.
  • Adapt management strategies based on available resources.
  • Work toward a unified, patient-centered approach to ACLF care.

Related Q&A

POCUS-Guided AKI Management in Cirrhosis: Hepatology | July 2026

Introduction: Acute kidney injury (AKI) is a frequent and life-threatening complication of cirrhosis, with management often complicated by inaccurate assessment of intravascular volume and the presence of cirrhotic cardiomyopathy (CCM). This prospective study evaluated whether...

A Novel Pro-Resolving Target (Annexin A1) for ACLF: Hepatology | May 2026

Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...

Distal Esophageal Varices in Fontan Circulation: Hepatology | May 2026

Introduction: Adults with Fontan-type circulation are increasingly recognized to develop Fontan-associated liver disease and portal hypertension. This prospective study explored the prevalence, anatomical distribution, and hemodynamic characteristics of esophageal varices (EV), with particular emphasis on...

Annexin A1-A Novel Pro-Resolving Target for ACLF: Hepatology | May 2026

Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...

Simvastatin Improves Survival After Variceal Bleeding in Cirrhosis: AJG | July 2026

Introduction: Despite advances in the management of portal hypertension, mortality after variceal bleeding remains high in patients with cirrhosis. Experimental and clinical studies suggest that statins may improve portal hypertension and hepatic vascular function. This...

Pre-Emptive CRRT Improves Outcomes in ALF with Cerebral Oedema: AP&T | June 2026

Introduction: Acute liver failure (ALF) complicated by cerebral oedema carries a high risk of early mortality, primarily due to hyperammonemia and intracranial hypertension. The optimal timing of continuous renal replacement therapy (CRRT) in these critically...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer